Company Presentations

The BioNJ 2013 International BioPartnering Conference Committee welcomes and encourages BioNJ Core Member (R&D) Companies to take part in this dynamic conference by securing a 15-minute presentation slot (10 minutes of presentation and 5 minutes for Q&A) at the Conference.

As part of the Company Presentation process, we are offering a Coaching Session for all presenters that will be provided by a panel of experienced industry experts. Considered one of the most beneficial aspects of the BioPartnering Conference, companies that have participated in previous Coaching Sessions reported that the coaching provided useful information that they used to improve their presentations for the International BioPartnering Conference and other venues.

 The following guidelines also apply to Presenting Companies:

  • Company Presenter will need to register for the Conference to secure a presentation slot.
  • Submission of an application form that includes a company description using BioNJ template. Click here for the application form.
  • Presenter must use the template provided by BioNJ for the slide presentation.
  • Presenter is expected to attend a Coaching Session – date(s) to be announced. The coaching session for each company will be approximately 45 minutes.
  • A presenting company must be a Biotech or Medtech company.  BioNJ Core Member Companies will be given selection preference.

We invite companies to submit their information as soon as possible. Contact Debbie Mennito of BioNJ at 609-890-3185 or via email at with any questions.

All-Star Investor Panel

Kathleen Coviello
Director of the Technology and Life Sciences Division
New Jersey Economic Development Authority

Kathleen Coviello is the Director of the Technology & Life Sciences Division (TLS) of the EDA. As such, she along with her team, are responsible for working closely with the early stage technology and life science companies and investors in the state and delivering the various Edison Innovation Fund products to this community.

Prior to joining the EDA, she spent over seventeen years in the banking industry, with the last eight focused exclusively on the NJ Technology Venture Lending Market. Her venture lending experience includes employment at Silicon Valley Bank, Comerica Bank and Progress’s Techbanc.

Coviello is active in the NJ entrepreneurial technology community and sits on the advisory and/or valuation boards of Edison Venture Fund, The Garden State Life Sciences Fund, and NJTC Venture Fund.

Pamela R. Demain, MBA, CLP 
Executive Director, Corporate Licensing
Merck & Co., Inc.

Pamela Demain is Executive Director, Corporate Licensing at Merck.  She has been at Merck for over 30 years. For the past 18 years, she has been responsible for negotiating transactions with companies, universities and institutions worldwide, including arrangements for compounds, research collaborations, patents, formulations and research platform technologies.

Pam also heads up the relationship development area, which includes responsibility for Merck’s partnering outreach program, initiating new business development opportunities and building relationships with companies and universities worldwide. Since 2000, she has been instrumental in the strategic transformation of Merck from an inward-looking to an outward-facing company focused on partnerships with companies and universities worldwide.

Prior to her current position, Ms. Demain was in charge of the Business Information & Research Department in the Worldwide Human Health Marketing area of Merck, providing global strategic decision support for all of Merck’s new and in-line products.

Previous positions at Merck include 13 years in Corporate Planning, Marketing Communications and Product Management, where she was responsible for the worldwide launch of PRIMAXIN/TIENAM.  She joined Merck in 1981 as part of the MBA management training program.

Pamela’s pharmaceutical career began in the natural products laboratory of Gruppo Lepetit, an Italian pharmaceutical company, which was then a subsidiary of the Dow Chemical Company.  Ms. Demain is a graduate of theUniversityofMassachusettsatAmherst, and holds a M.B.A. in International Business from The American University inWashington,D.C.and is a Certified Licensing Professional (CLP).

Pam has been on the Board of Trustees for the Licensing Executive Society (USA&Canada) since 2006 and is currently Vice President of Communications.  She previously was Regional VP for theUS, and Trustee for Partnering.  Her most recent accomplishments include establishing the LES Insights weekly e-newsletter, and the Branding Initiative for LES. She has been a member of the LES Life Sciences Committee since 2003. In 2012, she was honored by LES with the Frank Barnes Mentoring Award.

Robert Esposito, CPA
Director, Corporate Finance
EisnerAmper LLP
Panel Sponsor

Robert S. Esposito is a Director in the firm’s Corporate Finance Group.  He has more than 35 years of experience assisting clients with transaction strategy and execution, project management, accounting and auditing, SEC public offerings, and business strategy.

Bob’s expertise is concentrated primarily on the planning, management, and execution of due diligence and transaction structuring engagements for buy- and sell-side transactions.  He has significant experience with mergers and acquisitions, private equity investments, strategic alliances, and corporate joint ventures.  He also possesses deep industry expertise in the pharmaceutical, biotechnology, medical device, and pharmaceutical services industries.

Prior to joining EisnerAmper, Bob was a Senior Partner in a Big 4 Firm where he served as National Lead Partner for the Pharmaceutical, Biotechnology and Medical Device industry.  He was also National Lead Partner for the Transaction Services Practice – Life Sciences Industry.

Bob graduated from Rider University with a B.S. Accounting and a Masters in Accounting (Summa Cum Laude). Bob serves on Rider University’s Accounting Advisory Board and as an Executive-in-Residence.  He is a member of AICPA, NJSCPA, and PACPA.  In addition, Bob serves on the Advisory Board Committees of BioNJ and PaBio, and was a former Board Member for the Biotechnology Industry Organization (BIO).

Ben Goldberg
BSG Advisors
Angel Investor

Ben is the founder of BSG Advisors, a consulting firm with a practice focused on providing financial and operating management expertise to emerging growth and middle market companies, particularly in the technology, life sciences, cleantech, and advanced manufacturing industries.  He serves these clients as an interim or part-time CFO and/orCOO, or on a project or transaction, such as an acquisition, divestiture or licensing transaction, due diligence, strategic and operational planning and budgeting, business plan and investor presentation development, cash flow management, turnaround and crisis management, financing, or systems selection and implementation.  He also performs due diligence for early stage investors and assists them in transactions.

Prior to founding BSG Advisors, Ben served as CFO of a $20 million manufacturer of packaging materials and a $25 million manufacturer of bar code scanning equipment.  As CFO of the bar code scanning manufacturer, he served as a key member of a team that prepared the registration statement and prospectus for the company’s initial public offering effort.  His experience includes both high growth situations and successful turnarounds.  Earlier in his career, he worked for several Fortune 100 companies in positions in Engineering, Operations, and Financial Management.  He also taught in the Graduate Business School at Fairleigh Dickinson University.  Ben received his Bachelor’s degree in Industrial Engineering from Lehigh University and his Master’s degree in Business Administration from the University of Delaware.  He is active in a number of civic and charitable organizations and is a member of the Greater Philadelphia Senior Executives Group, BioStrategy Partners, Regional Biotech Council, MidAtlantic Angel Group, and Financial Executive Networking Group.  He has served as a judge of numerous business plan competitions including the Fox School Business Plan Competition, Mid-Atlantic Diamond Ventures and the Angel Venture Fair, and as a member of theScienceCenter’s QED Program selection team.  He serves as elected Auditor for his Township.

Ben is an active angel investor, as well as an entrepreneur.  He has been a leader in the Mid-Atlantic Angel Group Funds, serving as Treasurer of MAG I, chairman of the MAG I screening committee, member of the MAG I & II executive committees, and has led and participated in numerous due diligence assignments.  He is a member of the board of directors of MAG I portfolio companies NanoPack and Biopticon and as the MAG representative to SkillSurvey and Compliance Assurance.  Together with Larry Brotzge of RobinHood Ventures, Ben led the $1.1 million syndication of NanoPack among the four most prominent Philadelphia angel groups – MAG, RobinHood, Delaware Crossing and LORE.

Evan Myrianthopoulos
Managing Director, Life Science Investment Banking
Aegis Capital Corp.

Evan Myrianthopoulos is Managing Director of the life science investment banking practice at Aegis Capital. Evan also currently serves as an advisor to GPB Capital Corp.  Prior to joining Aegis, he formerly Chief Financial Officer of Soligenix, Inc., a clinical stage biopharmaceutical company based in Princeton NJ where he also served as a Board Director from 2002 until 2012.  Evan was also a co-founder and Board Director of Discovery Laboratories, Inc. While at Discovery from 1996 till 2001, Evan held the positions of Chief Financial Officer, Chief Operating Officer, and VP of Finance. He took Discovery public through reverse merger with Ansan Pharmaceuticals, Inc. and also managed its merger with Acute Therapeutics, Inc. During his tenures with Soligenix and Discovery, Mr. Myrianthopoulos led 17 financings totaling over $150 million in proceeds, 4 company acquisitions and 13 licensing deals. Prior to co-founding Discovery, Mr. Myrianthopoulos was in the venture capital group at Paramount Capital, Inc., a New York City based biotechnology investment bank. Prior to joining Paramount, Mr. Myrianthopoulos was a founder and managing partner of S&M Capital Management, a technology focused hedge fund, and also held senior positions in the treasury departments at the National Australia Bank and Merita Bank where he was employed as a spot currency trader. Mr. Myrianthopoulos holds a B.A. in Economics and Psychology from Emory University.

Eric T. Olson, MBA
Sanofi-Genzyme BioVentures

Eric Olson is a Director on the Sanofi-Genzyme BioVentures team and was previously a Senior Associate of Genzyme Ventures.  Prior to joining Genzyme Ventures, Eric was a Business Development Manager in Genzyme’s Corporate Development group, where he evaluated and led numerous business development opportunities spanning several therapeutics areas and stages of development. Prior to joining Genzyme, Eric was an investment banker at Benedetto, Gartland & Co., a boutique that specialized in raising private equity for select private equity sponsors and corporations.  Eric began his career as a Research Assistant at the Yale University School of Medicine, where he published several papers in peer-reviewed journals.

Eric holds an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia, an M.S. in Cellular and Molecular Biology from New York University, and a B.A. in Zoology from Connecticut College.

Katherine O’Neill
Executive Director
JumpStart New Jersey Angel Network

Katherine O’Neill is the Executive Director for JumpStart New Jersey Angel Network, a member led angel investor group that invests in early stage companies in Mid-Atlantic region. She is an investor in early stage growth companies.  She currently serves on the Board of the Angel Capital Association ACA the national organization representing angel investor groups in North America. Katherine represents the ACA at both national and international events.

Katherine is a member of the NJ Economic Development Authority Edison Fund Advisory Board, Ben Franklin Technology Partners of SEPA Advisory Board, NJ Technology CFO Advisory Board, Princeton University MIRTHE Investment Focus Group and Rutgers Innovation Park Advisory Board. In recent years she has spoken at and judged business plan competitions both regionally and nationally at events such as IMPACT, Astia, Microsoft BizSpark NYC competition, Tri State Donald W. Reynolds Cup, Princeton University Jumpstart Innovation Forum and Start Up Weekend Princeton.  She is a mentor at regional accelerators Princeton University E-Labs and TechLaunch.

Katherine is a seasoned financial executive and investor in early stage enterprises with extensive experience in start up and entrepreneurial operations as well as operational experiences in a diverse range of businesses.  She has particular expertise developing technology-based business as well as strategic business plans. She has extensive multi-national experience and financial operation management and expertise in healthcare, biotech, pharmaceuticals, information systems, e-commerce and social media.  She is the president of O’Neill Associates and consults with growth companies and acts as interim CFO.

In addition to her entrepreneurial activities, she was a senior executive in corporate finance in both a Fortune 100 pharmaceutical company  the now GlaxoSmithKline and Fortune 500 chemical company FMC. Katherine has served on many non-profit boards focusing on education and women in business.  Katherine is also currently active with the Forum of Executive Women and the New Jersey Technology Council.  Katherine earned BA in Economics from the University of Maryland Munich, Germany and College Park and a MA in Economics from the University of Pennsylvania.

Lorenzo Pellegrini, Ph.D.
Care Capital, LLC

Prior to joining Care Capital, Dr. Pellegrini was a post-doctoral research fellow in the Department of Cell Biology at Yale University, where he investigated the molecular basis of neuronal signaling and receptor internalization. During his ten-year tenure as an academic research scientist, Dr. Pellegrini published original research in several leading peer-reviewed scientific journals, including Nature, Cell and Neuron among others, and was awarded a number of awards, including EMBO and Howard Hughes Medical Institute fellowships.

Dr. Pellegrini holds a Laurea in Chemistry, summa cum laude, from the University of Padova, Italy, a Ph.D. in Biochemistry from the Max-Planck-Institute for Brain Research in Frankfurt am Main, Germany, and an M.B.A. with Honors from The Wharton School of the University of Pennsylvania.

Yaniv Sneor
Mid Atlantic BioAngels

Yaniv Sneor is an entrepreneur, consultant and one of the founders of MABA (Mid Atlantic Bio Angels – a life science angel investment group.  He has more than 20 years experience starting, running and restructuring companies, in a variety of industries.  Through his consulting practice (Blue Cactus Consulting), Mr. Sneor assists companies with strategy, execution and technology commercialization.

Tracy Warren
General Partner
Battelle Ventures, LP

Tracy Warren is a general partner of Battelle Ventures and Innovation Valley Partners, for which she focuses on investments in health & life sciences and emerging energy technologies.

Tracy has worked closely on identifying promising technologies, projects and synergies with the National Laboratories that sole limited partner Battelle manages or co-manages for the U.S. Department of Energy around the country. For example, alongside Dr. Cymbeline Culiat, she co-founded and led the funds’ investments in NellOne Therapeutics, a soft-tissue regenerative medicine company based on the NELL1 gene and Dr. Culiat’s work at Oak Ridge National Laboratory.

Tracy has also co-founded other life-sciences companies, such as university spin-out Endovalve (cardiovascular devices / University of Pennsylvania, merged with Micro Interventional Devices in April 2011), and has led investments in others, such as BioNano Genomics (genetic analysis / Princeton University) and NuPathe (CNS specialty pharmaceutical; NASDAQ: PATH), which completed its IPO in 2010.

Today, she is chairman of the BioNano Genomics Board of Directors and sits on the board of Micro Interventional Devices.

On the energy front, as a strong syndicate partner, Tracy also led the funds’ investment in SmartSynch (utility smart metering), which was acquired in 2012 by Itron, Inc. (NASDAQ:ITRI).

In addition to her investment activities, Tracy also provides early-stage leadership to several other life-sciences businesses, currently serving as a business adviser to PDX Pharmaceuticals, LLC, and VOX Telehealth.

Tracy started in venture capital more than a decade ago, after being an associate in SG Cowen (now Cowen and Company) Securities & Health Care Mergers and Acquisitions and Corporate Finance divisions. She holds a B.S. degree from New York University Stern School of Business and an M.B.A from Columbia Business School.